Felix Korell

917 total citations
22 papers, 329 citations indexed

About

Felix Korell is a scholar working on Oncology, Biomedical Engineering and Immunology. According to data from OpenAlex, Felix Korell has authored 22 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 7 papers in Biomedical Engineering and 4 papers in Immunology. Recurrent topics in Felix Korell's work include CAR-T cell therapy research (19 papers), Advancements in Semiconductor Devices and Circuit Design (4 papers) and Nanowire Synthesis and Applications (4 papers). Felix Korell is often cited by papers focused on CAR-T cell therapy research (19 papers), Advancements in Semiconductor Devices and Circuit Design (4 papers) and Nanowire Synthesis and Applications (4 papers). Felix Korell collaborates with scholars based in Germany, United States and United Kingdom. Felix Korell's co-authors include Marcela V. Maus, Marco Ruella, Patrizia Porazzi, Peter Dreger, Trisha R. Berger, Michael Schmitt, Carsten Müller‐Tidow, Anita Schmitt, Maria‐Luisa Schubert and Thomas Luft and has published in prestigious journals such as Blood, Nature Reviews Drug Discovery and Cancer Research.

In The Last Decade

Felix Korell

20 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Felix Korell Germany 10 258 78 78 76 60 22 329
Xiaoqian Liang China 6 243 0.9× 117 1.5× 98 1.3× 54 0.7× 68 1.1× 8 334
Wenli Zhang China 10 203 0.8× 87 1.1× 78 1.0× 35 0.5× 68 1.1× 26 298
Miriam Sánchez‐Escamilla Spain 5 193 0.7× 56 0.7× 66 0.8× 50 0.7× 72 1.2× 13 239
Marta García‐Recio Spain 6 245 0.9× 46 0.6× 39 0.5× 39 0.5× 71 1.2× 12 294
Aishat Olaide Afuye United States 4 250 1.0× 46 0.6× 39 0.5× 44 0.6× 79 1.3× 4 275
Yanzhi Song China 7 200 0.8× 39 0.5× 27 0.3× 50 0.7× 60 1.0× 21 244
Mari Lynne Silverberg Thailand 2 227 0.9× 43 0.6× 33 0.4× 38 0.5× 71 1.2× 2 246
Agrima Mian United States 8 151 0.6× 47 0.6× 20 0.3× 32 0.4× 33 0.6× 36 248
Ali Bukhari United States 9 206 0.8× 45 0.6× 27 0.3× 40 0.5× 45 0.8× 25 297

Countries citing papers authored by Felix Korell

Since Specialization
Citations

This map shows the geographic impact of Felix Korell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felix Korell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felix Korell more than expected).

Fields of papers citing papers by Felix Korell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Felix Korell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felix Korell. The network helps show where Felix Korell may publish in the future.

Co-authorship network of co-authors of Felix Korell

This figure shows the co-authorship network connecting the top 25 collaborators of Felix Korell. A scholar is included among the top collaborators of Felix Korell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Felix Korell. Felix Korell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Korell, Felix, Irene Scarfò, Harrison Silva, et al.. (2025). Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma. Leukemia. 39(10). 2452–2464. 1 indexed citations
2.
Koeckerling, David, Rohin K. Reddy, Joseph Barker, et al.. (2024). Cardiovascular Events After Chimeric Antigen Receptor T-Cell Therapy for Advanced Hematologic Malignant Neoplasms. JAMA Network Open. 7(10). e2437222–e2437222. 9 indexed citations
3.
Korell, Felix, Michael Olson, Diego Salas‐Benito, et al.. (2024). Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics. Science Translational Medicine. 16(750). eadk7640–eadk7640. 14 indexed citations
4.
Lee, Won‐Ho, Charlotte Graham, Felix Korell, et al.. (2024). Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood. Cytometry Part B Clinical Cytometry. 106(3). 162–170.
5.
Schubert, Maria‐Luisa, Peter Dreger, Anita Schmitt, et al.. (2024). Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study. Leukemia. 38(11). 2419–2428. 18 indexed citations
6.
Korell, Felix, Evangelos Giannitsis, Anita Schmitt, et al.. (2024). Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study. EClinicalMedicine. 69. 102504–102504. 14 indexed citations
7.
Ruella, Marco, Felix Korell, Patrizia Porazzi, & Marcela V. Maus. (2023). Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nature Reviews Drug Discovery. 22(12). 976–995. 67 indexed citations
8.
Korell, Felix, Michael Olson, Diego Salas‐Benito, et al.. (2023). Abstract 4098: Chimeric antigen receptor (CAR) T cells overexpressing Bcl-xL increase proliferation and antitumor activity alone and in combination with BH3 mimetics. Cancer Research. 83(7_Supplement). 4098–4098. 3 indexed citations
9.
Bunse, Lukas, Claudia Sommerer, Chin Leng Tan, et al.. (2022). Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV. International Journal of Molecular Sciences. 23(3). 1029–1029. 2 indexed citations
10.
Korell, Felix, Trisha R. Berger, & Marcela V. Maus. (2022). Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes. Med. 3(8). 538–564. 45 indexed citations
11.
Korell, Felix, Olaf Penack, Mike Mattie, et al.. (2022). EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study. Frontiers in Immunology. 13. 877477–877477. 32 indexed citations
12.
Korell, Felix, et al.. (2022). Combinatorial Effects of BH3 Mimetics and CAR T Cells Targeting T-Cell Lymphomas. Blood. 140(Supplement 1). 499–500. 1 indexed citations
13.
14.
15.
Luft, Thomas, Clemens‐Martin Wendtner, Aleksandar Radujkovic, et al.. (2021). EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients. Frontiers in Immunology. 12. 35 indexed citations
16.
17.
Korell, Felix, Maria‐Luisa Schubert, Tim Sauer, et al.. (2021). Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy. Blood. 138(Supplement 1). 4835–4835. 1 indexed citations
18.
Korell, Felix, Evangelos Giannitsis, Uta Merle, & Lars Kihm. (2020). <p>Analysis of Symptoms of COVID-19 Positive Patients and Potential Effects on Initial Assessment</p>. Open Access Emergency Medicine. Volume 12. 451–457. 5 indexed citations
19.
Korell, Felix, Thomas Luft, Michael Schmitt, et al.. (2020). Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL). Blood. 136(Supplement 1). 11–12. 1 indexed citations
20.
Korell, Felix, Sandra Sauer, Kaya Veelken, et al.. (2020). Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL. Cells. 9(5). 1225–1225. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaoqian Liang Breakdown of academic impact, for papers by Wenli Zhang Breakdown of academic impact, for papers by Miriam Sánchez‐Escamilla Breakdown of academic impact, for papers by Marta García‐Recio Breakdown of academic impact, for papers by Aishat Olaide Afuye Breakdown of academic impact, for papers by Yanzhi Song Breakdown of academic impact, for papers by Mari Lynne Silverberg Breakdown of academic impact, for papers by Agrima Mian Breakdown of academic impact, for papers by Ali Bukhari
Rankless by CCL
2026